Skip to main content

Urgo patient

Menu
URGO MEDICAL Healing People

UrgoStart Border Product Image

Take control of healing, close wounds sooner

Effective, Evidence-Based and Easy-to-Use Solution with

2 benefits: Heals and closes wounds sooner1,2,3

What is UrgoStart Border

UrgoStart Border is an adhesive silicone foam dressing with borders, designed to absorb wound exudate. It is coated with the Technology Lipido-Colloid–Nano-Oligo Saccharide Factor (TLC-NOSF).

Its silicone border ensures secure adhesion and protection, and its absorbent foam and superabsorbent layer ensure high absorption to manage exudate.

UrgoStart Border Dressing

TLC-NOSF Technology TLC-NOSF Technology

The TLC-NOSF technology effectively heals and closes wounds sooner.

Effectively Heals1,2

Effectively Heals

Healing matrix reduces MMP levels and restores balance

Restores balance to the patient’s healing trajectory

Closes Sooner1,2,3

Closes Sooner

Closes wounds sooner than other dressings

The sooner you implement it, the better the outcomes4,5

The benefits of TLC-NOSF TLC-NOSF Technology

✓
Reduces excess matrix metalloproteinases (MMP), which are associated with delayed healing in chronic wounds.6
✓
Maintains a moist healing environment.6
✓
Provides atraumatic and pain-free removal.7
✓
Helps restore balance in the wound to heal wound sooner.1,2,3

When to Use UrgoStart Border

UrgoStart Border is suitable for managing a range of wound types and situations requiring a silicone foam dressing with border for secure fit and protection.

Chronic wounds:

  • Leg ulcers
  • Diabetic foot ulcers
  • Pressure ulcers
  • Other long-lasting or recurrent wounds

Wounds at risk of delayed healing

How to use UrgoStart Border dressing

1

Prepare the wound

Clean the wound using local protocol.

If an antiseptic was used, rinse thoroughly with sterile saline.

Gently dry the skin around the wound.

2

Apply the UrgoStart Border Dressing

UrgoStart Border consists of several absorbent layers that must not be cut. Only the adhesive border can be cut with sterile scissors where it can facilitate application and dressing securement.

Remove the protective wings from the silicone dressing.

Apply the soft-adherent side (with TLC-NOSF) directly onto the wound be careful to place the adhesive border at least one centimetre (1 cm) from the wound edges.

Ensure the silicone border adheres smoothly to surrounding skin.

Smooth the dressing to remove any wrinkles or gaps.

If needed, apply compression bandaging over the dressing.

Special Instructions – Sacrum Version

Position the silicone dressing with the tip facing the sacral area for optimal coverage.

UrgoStart Border Step 2 - application
3

Remove the Dressing

Press down gently on surrounding healthy skin.

Lift one corner of the dressing and peel off carefully to avoid trauma.

UrgoStart Border Step 3 - removal

FEATURES

FEATURES BENEFITS

Effective in closing wounds sooner with its TLC-NOSF technology1,2,3

✔️ Reduces excess MMPs.6

✔️ Creates and maintains moist environment.6

✔️ Atraumatic and painless removal.7

Evidence-based

✔️ First and only dressing recommended by the IWGDF.8

✔️ Recommended by the NICE guidelines.9

✔️ Efficacy proven by a robust pyramid of evidence which includes systematic reviews, RCT, observational studies and local case reports.

Easy to Use

✔️ Easy to implement in current care pathways as part of the standard of care to improve healing outcomes.

Additional Features

✔️ Silicone foam dressing with border for secure fit and gentle adhesion.

✔️ High exudate management to prevent maceration.

✔️ The vapour-permeable, waterproof silicone backing is soft, conformable and non-occlusive. It also prevents fluid leakage and bacteria strikethrough.

✔️ Due to its transparency, it is possible to monitor fluid strikethrough, enabling you to change the dressing only when needed.

✔️ Supports self-care and showerproof use.

Get in Touch with Our Representative for More Information About UrgoStart Border

Contact us

References

  1. Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, Martini J, Petit JM, Rayman G, Lobmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3):186-196.
  2. Münter KC, Meaume S, Augustin M, Senet P, Kérihuel JC. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care 2017; 26(Sup2): S4-S15. doi: 10.12968/jowc.2017.26.Sup2.S4
  3. Lazaro et al . Optimal wound closure of diabetic foot ulcers with early initiation of TLC-NOSF treatment: post-hoc analysis of Explorer. JWC VOL 28, NO 6 , June 2019
  4. Dissemond J, Lützkendorf S, Dietlein M, Neßeler I, Becker E, Möller U, Thomassin L, Bohbot S, Münter KC. Clinical evaluation of polyabsorbent TLC-NOSF dressings on chronic wounds: a prospective, observational, multicentre study of 1140 patients. J Wound Care. 2020 Jun 2;29(6):350-361. doi: 10.12968/jowc.2020.29.6.350. PMID: 32530781.
  5. Meloni M, Colboc H, Armstrong DG, Dissemond J, Rayman G, Lázaro-Martínez JL, Rial R, Hartemann A, Atkin L, Swanson T, Goodeve M, Lobmann R, Storck M, Kröger K, Borys S, Nair HK, Vaidya S, Tran TN, Huynh BLT, Thomassin L, Bohbot S, Manu C, Meaume S. TLC-NOSF dressings as a first-line local treatment of chronic wounds: a systematic review of clinical evidence. J Wound Care. 2024 Oct 2;33(10):756-770. doi: 10.12968/jowc.2024.0208. PMID: 39388207.
  6. “In vitro” study. Internal Report. Laboratoires URGO.
  7. Schmutz J.L. et al. Evaluation of the nano-oligosaccharide factor lipido-colloid matrix in the local management of venous leg ulcers : results of a randomised, controlled trial. Int Wound J 2008;5:172–182
  8. Chen P, Campillo Vilorio N, Dhatariya K et al. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes. IWGDF 2023 update. Diabetes Metab Res Rev 2024; 40(3):e3644. https://doi.org/10.1002/dmrr.3644
  9. National Institute for Health and Care Excellence (NICE), UrgoStart for treating leg ulcers and diabetic foot ulcers, https://www.nice.org.uk/guidance/mtg42, April 2023.

INDICATIONS

UrgoStart Border is indicated for covering and treating the following skin wounds:

  • Leg ulcers
  • Diabetic foot ulcers
  • Pressure ulcers (bedsores)
  • Other long-lasting or recurrent wounds or wounds at risk of long lasting

UrgoStart Border is intended for use on wounds mainly covered with granulation tissue (red budding tissue in the wound).

Get in Touch with Our Representative for More Information About UrgoStart Border

Contact us

References

  1. Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, Martini J, Petit JM, Rayman G, Lobmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3):186-196.
  2. Münter KC, Meaume S, Augustin M, Senet P, Kérihuel JC. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care 2017; 26(Sup2): S4-S15. doi: 10.12968/jowc.2017.26.Sup2.S4
  3. Lazaro et al . Optimal wound closure of diabetic foot ulcers with early initiation of TLC-NOSF treatment: post-hoc analysis of Explorer. JWC VOL 28, NO 6 , June 2019
  4. Dissemond J, Lützkendorf S, Dietlein M, Neßeler I, Becker E, Möller U, Thomassin L, Bohbot S, Münter KC. Clinical evaluation of polyabsorbent TLC-NOSF dressings on chronic wounds: a prospective, observational, multicentre study of 1140 patients. J Wound Care. 2020 Jun 2;29(6):350-361. doi: 10.12968/jowc.2020.29.6.350. PMID: 32530781.
  5. Meloni M, Colboc H, Armstrong DG, Dissemond J, Rayman G, Lázaro-Martínez JL, Rial R, Hartemann A, Atkin L, Swanson T, Goodeve M, Lobmann R, Storck M, Kröger K, Borys S, Nair HK, Vaidya S, Tran TN, Huynh BLT, Thomassin L, Bohbot S, Manu C, Meaume S. TLC-NOSF dressings as a first-line local treatment of chronic wounds: a systematic review of clinical evidence. J Wound Care. 2024 Oct 2;33(10):756-770. doi: 10.12968/jowc.2024.0208. PMID: 39388207.
  6. “In vitro” study. Internal Report. Laboratoires URGO.
  7. Schmutz J.L. et al. Evaluation of the nano-oligosaccharide factor lipido-colloid matrix in the local management of venous leg ulcers : results of a randomised, controlled trial. Int Wound J 2008;5:172–182
  8. Chen P, Campillo Vilorio N, Dhatariya K et al. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes. IWGDF 2023 update. Diabetes Metab Res Rev 2024; 40(3):e3644. https://doi.org/10.1002/dmrr.3644
  9. National Institute for Health and Care Excellence (NICE), UrgoStart for treating leg ulcers and diabetic foot ulcers, https://www.nice.org.uk/guidance/mtg42, April 2023.

CONTRAINDICATIONS

UrgoStart Border is contraindicated in:

  • Mucous membrane wounds.
  • Malignant wounds.
  • Fistula wounds.
  • Known hypersensitivity of the patient to one of the TLC or TLC-NOSF dressings, or to carboxymethylcellulose (CMC).

Get in Touch with Our Representative for More Information About UrgoStart Border

Contact us

References

  1. Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, Martini J, Petit JM, Rayman G, Lobmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3):186-196.
  2. Münter KC, Meaume S, Augustin M, Senet P, Kérihuel JC. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care 2017; 26(Sup2): S4-S15. doi: 10.12968/jowc.2017.26.Sup2.S4
  3. Lazaro et al . Optimal wound closure of diabetic foot ulcers with early initiation of TLC-NOSF treatment: post-hoc analysis of Explorer. JWC VOL 28, NO 6 , June 2019
  4. Dissemond J, Lützkendorf S, Dietlein M, Neßeler I, Becker E, Möller U, Thomassin L, Bohbot S, Münter KC. Clinical evaluation of polyabsorbent TLC-NOSF dressings on chronic wounds: a prospective, observational, multicentre study of 1140 patients. J Wound Care. 2020 Jun 2;29(6):350-361. doi: 10.12968/jowc.2020.29.6.350. PMID: 32530781.
  5. Meloni M, Colboc H, Armstrong DG, Dissemond J, Rayman G, Lázaro-Martínez JL, Rial R, Hartemann A, Atkin L, Swanson T, Goodeve M, Lobmann R, Storck M, Kröger K, Borys S, Nair HK, Vaidya S, Tran TN, Huynh BLT, Thomassin L, Bohbot S, Manu C, Meaume S. TLC-NOSF dressings as a first-line local treatment of chronic wounds: a systematic review of clinical evidence. J Wound Care. 2024 Oct 2;33(10):756-770. doi: 10.12968/jowc.2024.0208. PMID: 39388207.
  6. “In vitro” study. Internal Report. Laboratoires URGO.
  7. Schmutz J.L. et al. Evaluation of the nano-oligosaccharide factor lipido-colloid matrix in the local management of venous leg ulcers : results of a randomised, controlled trial. Int Wound J 2008;5:172–182
  8. Chen P, Campillo Vilorio N, Dhatariya K et al. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes. IWGDF 2023 update. Diabetes Metab Res Rev 2024; 40(3):e3644. https://doi.org/10.1002/dmrr.3644
  9. National Institute for Health and Care Excellence (NICE), UrgoStart for treating leg ulcers and diabetic foot ulcers, https://www.nice.org.uk/guidance/mtg42, April 2023.

PRECAUTIONS

  • If the periwound skin is weakened, the use of UrgoStart Border, which has an adhesive border, is left to the discretion of the healthcare professional.
  • In the event of signs or symptoms of infection before or after starting treatment with UrgoStart Border, such as erythema (redness of the skin around the wound), oedema (swelling), heat or pain in the wound area, fever, enlargement of the wound, odour from the wound, or profuse exudate (that is, a large amount of fluid in the wound), consult a healthcare professional for appropriate treatment.
  • In the event of overgranulation (excessive raised formation of red budding tissue on the wound) before or after starting treatment with UrgoStart Border, it must be reported to a healthcare professional for appropriate care.

For a complete list of precautions, contraindications, and indications, please contact your local sales representative to obtain the Instructions for Use (IFU).

Get in Touch with Our Representative for More Information About UrgoStart Border

Contact us

References

  1. Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, Martini J, Petit JM, Rayman G, Lobmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3):186-196.
  2. Münter KC, Meaume S, Augustin M, Senet P, Kérihuel JC. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care 2017; 26(Sup2): S4-S15. doi: 10.12968/jowc.2017.26.Sup2.S4
  3. Lazaro et al . Optimal wound closure of diabetic foot ulcers with early initiation of TLC-NOSF treatment: post-hoc analysis of Explorer. JWC VOL 28, NO 6 , June 2019
  4. Dissemond J, Lützkendorf S, Dietlein M, Neßeler I, Becker E, Möller U, Thomassin L, Bohbot S, Münter KC. Clinical evaluation of polyabsorbent TLC-NOSF dressings on chronic wounds: a prospective, observational, multicentre study of 1140 patients. J Wound Care. 2020 Jun 2;29(6):350-361. doi: 10.12968/jowc.2020.29.6.350. PMID: 32530781.
  5. Meloni M, Colboc H, Armstrong DG, Dissemond J, Rayman G, Lázaro-Martínez JL, Rial R, Hartemann A, Atkin L, Swanson T, Goodeve M, Lobmann R, Storck M, Kröger K, Borys S, Nair HK, Vaidya S, Tran TN, Huynh BLT, Thomassin L, Bohbot S, Manu C, Meaume S. TLC-NOSF dressings as a first-line local treatment of chronic wounds: a systematic review of clinical evidence. J Wound Care. 2024 Oct 2;33(10):756-770. doi: 10.12968/jowc.2024.0208. PMID: 39388207.
  6. “In vitro” study. Internal Report. Laboratoires URGO.
  7. Schmutz J.L. et al. Evaluation of the nano-oligosaccharide factor lipido-colloid matrix in the local management of venous leg ulcers : results of a randomised, controlled trial. Int Wound J 2008;5:172–182
  8. Chen P, Campillo Vilorio N, Dhatariya K et al. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes. IWGDF 2023 update. Diabetes Metab Res Rev 2024; 40(3):e3644. https://doi.org/10.1002/dmrr.3644
  9. National Institute for Health and Care Excellence (NICE), UrgoStart for treating leg ulcers and diabetic foot ulcers, https://www.nice.org.uk/guidance/mtg42, April 2023.

CUTTING GUIDE

Get in Touch with Our Representative for More Information About UrgoStart Border

Contact us

References

Guidelines, based on systematic review of clinical evidence

  1. National Institute for Health and Care Excellence (NICE). UrgoStart for treating leg ulcers and diabetic foot ulcers, https://www.nice.org.uk/guidance/mtg42, January 2019, last updated April 2023.
  2. Chen P, Campillo Vilorio N , Dhatariya K, Jeffcoate W , Lobmann R , McIntosh C , Piaggesi A , Steinberg J, Vas P, Viswanathan V, Wu S, Game F, on behalf of the International Working Group on the Diabetic Foot (IWGDF). Guidelines on interventions to enhance healing of foot ulcers in people with diabetes. IWGDF 2023 update. April 2023. Accessible at: Wound healing interventions guideline (2023 update) – IWGDF Guidelines

Systematic reviews

  1. Dissemond J, Augustin M, Dietlein M, Faust U, Keuthage W, Lobmann R, Münter KC, Strohal R, Stücker M, Traber J, Vanscheidt W, Läuchli S. Efficacy of MMP-inhibiting wound dressings in the treatment of chronic wounds: a systematic review. J Wound Care 2020 ; 29(2): 102-118.
  2. Nair H, Galea E, Deng W, Uthaipaisanwong A, Venkateshwaran N, Selva Seetha Raman S. Benefits of sucrose octasulfate (TLC-NOSF) dressings in the treatment of chronic wounds: A systematic review. Journal of Wound Care 2021; 30 (Suppl.4): S42-S52. doi: 10.12968/jowc.2021.30.Sup4.S42
  3. Vas P, Rayman G, Dhatariya K, Driver V, Hartemann A, Londahl M, Piaggesi A, Apelqvist J, Attinger C, Game F.Vas P, et al. Effectiveness of interventions to enhance healing of chronic foot ulcers in diabetes: a systematic review. Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3284. doi: 10.1002/dmrr.3284

Randomised Controlled Trials

  1. Meaume S, Truchetet F, Cambazard F et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-oligosaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair Regen 2012; 20: 4: 500-511. doi: 10.1111/j.1524-475X.2012.00797.x [Study conducted with Urgostart]
  2. Meaume S, Dompmartin A, Lazareth I, Sigal M, Truchetet F, Sauvadet A, Bohbot S. Quality of life in patients with leg ulcers: results from CHALLENGE, a double-blind randomized controlled trial. Journal of Wound Care 2017; 26 (7): 368-379. doi: 10.12968/jowc.2017.26.7.368 [Study conducted with Urgostart]
  3. Schmutz J.-L., Meaume S, Fays S, Ourabah Z, Guillot B, Thirion V, Collier M, Barrett S, Smith J, Bohbot S, Dompmartin A et al. Evaluation of the nano-oligosaccharide factor lopido-colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal 2008; 5(2): 172-182. [Study conducted with Urgostart contact]
  4. Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, Martini J, Petit JM, Rayman G, Lobmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3):186-196. [Study conducted with Urgostart contact]
  5. Lázaro-Martínez JL, Edmonds M, Rayman G, Apelqvist J, Van Acker K, Hartemann A, Martini J, Lobmann R, Bohbot S, Kerihuel JC, Piaggesi A. Optimal wound closure of diabetic foot ulcers with early initiation of TLC-NOSF treatment: post-hoc analysis of Explorer. J Wound Care 2019; 28(6): 358-367. doi: 10.12968/jowc.2019.28.6.358. PMID: 31166858. [Study conducted with Urgostart contact]

Interventional studies (non-comparative clinical trials)

  1. Sigal ML, Addala A, Maillard H, Chahim M, Sala F, Blaise S, Dalac S, Meaume S, Bohbot S, Tumba C, Tacca O. Clinical evaluation of a new TLC-NOSF dressing with poly-absorbent fibers for the local management of exuding leg ulcers, at the different stages of the healing process: Results from two multicentric, single-arm, prospective, open-label clinical trials. J Wound Care 2019: 28(3) :164-175. doi: 10.12968/jowc.2019.28.3.164 [Study conducted with Urgostart Plus pad]

Observational studies (real-life clinical studies)

  1. Münter KC, Meaume S, Augustin M, Senet P, Kérihuel JC. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care 2017; 26(Sup2): S4-S15. doi: 10.12968/jowc.2017.26.Sup2.S4 [Study conducted with Urgostart contact, Urgostart or Cellostart]
  2. Dissemond J, Lützkendorf S, Dietlein M, Neßeler I, Becker E, Möller U, Thomassin L, Bohbot S, Münter KC. Clinical evaluation of polyabsorbent TLC-NOSF dressings on chronic wounds: a prospective, observational, multicentre study of 1140 patients. J Wound Care 2020; 29 (6): 350-361. doi: 10.12968/jowc.2020.29.6.350 [Study conducted with Urgostart Plus pad and Urgostart Plus Border]
  3. Mai TT, & Trần QN. Tính hiệu quả và an toàn của gạc sucrose octasulfate trên vết loét bàn chân đái tháo đường: kết quả từ một nghiên cứu quan sát, nhãn mở, đa trung tâm tại Việt Nam. (Nội tiết và Đái tháo đường) Vietnam Journal of Diabetes and Endocrinology 2021; 45: 38-44. https://doi.org/10.47122/vjde.2020.45.6

Case Series & Case Reports

  1. Long Z, Jun W, Shijun Z, Dong J, Xinzhao F, Galea E. Diabetic foot ulcer management with TLC-NOSF (Technology Lipido-colloid Nano-oligosaccharide Factor) wound dressings. Wounds International 2021; 12(4): 54-61
  2. Wenge C, Xingbo Y, Jin Z et al (2022) Nano-oligosaccharide factor (sucrose octasulfate dressing based on technology lipido-colloid,TLC-NOSF) in the management of diabetic foot ulcers. The Diabetic Foot Journal 25(2): 1–6
  3. Nair HKR. Real life Experience Treating Chronic Wounds with UrgoStart Range (TLC-NOSF) – A case series. Urgo publication, 2022

DIRECTIONS FOR USE

Get in Touch with Our Representative for More Information About UrgoStart Border

Contact us

References

  1. Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, Martini J, Petit JM, Rayman G, Lobmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3):186-196.
  2. Münter KC, Meaume S, Augustin M, Senet P, Kérihuel JC. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care 2017; 26(Sup2): S4-S15. doi: 10.12968/jowc.2017.26.Sup2.S4
  3. Lazaro et al . Optimal wound closure of diabetic foot ulcers with early initiation of TLC-NOSF treatment: post-hoc analysis of Explorer. JWC VOL 28, NO 6 , June 2019
  4. Dissemond J, Lützkendorf S, Dietlein M, Neßeler I, Becker E, Möller U, Thomassin L, Bohbot S, Münter KC. Clinical evaluation of polyabsorbent TLC-NOSF dressings on chronic wounds: a prospective, observational, multicentre study of 1140 patients. J Wound Care. 2020 Jun 2;29(6):350-361. doi: 10.12968/jowc.2020.29.6.350. PMID: 32530781.
  5. Meloni M, Colboc H, Armstrong DG, Dissemond J, Rayman G, Lázaro-Martínez JL, Rial R, Hartemann A, Atkin L, Swanson T, Goodeve M, Lobmann R, Storck M, Kröger K, Borys S, Nair HK, Vaidya S, Tran TN, Huynh BLT, Thomassin L, Bohbot S, Manu C, Meaume S. TLC-NOSF dressings as a first-line local treatment of chronic wounds: a systematic review of clinical evidence. J Wound Care. 2024 Oct 2;33(10):756-770. doi: 10.12968/jowc.2024.0208. PMID: 39388207.
  6. “In vitro” study. Internal Report. Laboratoires URGO.
  7. Schmutz J.L. et al. Evaluation of the nano-oligosaccharide factor lipido-colloid matrix in the local management of venous leg ulcers : results of a randomised, controlled trial. Int Wound J 2008;5:172–182
  8. Chen P, Campillo Vilorio N, Dhatariya K et al. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes. IWGDF 2023 update. Diabetes Metab Res Rev 2024; 40(3):e3644. https://doi.org/10.1002/dmrr.3644
  9. National Institute for Health and Care Excellence (NICE), UrgoStart for treating leg ulcers and diabetic foot ulcers, https://www.nice.org.uk/guidance/mtg42, April 2023.

PRODUCT OPTIONS

Product Size Units/Box
8x8cm 10
10x10cm 10
13x13cm 10
15x20cm 10
Sacrum 5

Get in Touch with Our Representative for More Information About UrgoStart Border

Contact us

References

Guidelines, based on systematic review of clinical evidence

  1. National Institute for Health and Care Excellence (NICE). UrgoStart for treating leg ulcers and diabetic foot ulcers, https://www.nice.org.uk/guidance/mtg42, January 2019, last updated April 2023.
  2. Chen P, Campillo Vilorio N , Dhatariya K, Jeffcoate W , Lobmann R , McIntosh C , Piaggesi A , Steinberg J, Vas P, Viswanathan V, Wu S, Game F, on behalf of the International Working Group on the Diabetic Foot (IWGDF). Guidelines on interventions to enhance healing of foot ulcers in people with diabetes. IWGDF 2023 update. April 2023. Accessible at: Wound healing interventions guideline (2023 update) – IWGDF Guidelines

Systematic reviews

  1. Dissemond J, Augustin M, Dietlein M, Faust U, Keuthage W, Lobmann R, Münter KC, Strohal R, Stücker M, Traber J, Vanscheidt W, Läuchli S. Efficacy of MMP-inhibiting wound dressings in the treatment of chronic wounds: a systematic review. J Wound Care 2020 ; 29(2): 102-118.
  2. Nair H, Galea E, Deng W, Uthaipaisanwong A, Venkateshwaran N, Selva Seetha Raman S. Benefits of sucrose octasulfate (TLC-NOSF) dressings in the treatment of chronic wounds: A systematic review. Journal of Wound Care 2021; 30 (Suppl.4): S42-S52. doi: 10.12968/jowc.2021.30.Sup4.S42
  3. Vas P, Rayman G, Dhatariya K, Driver V, Hartemann A, Londahl M, Piaggesi A, Apelqvist J, Attinger C, Game F.Vas P, et al. Effectiveness of interventions to enhance healing of chronic foot ulcers in diabetes: a systematic review. Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3284. doi: 10.1002/dmrr.3284

Randomised Controlled Trials

  1. Meaume S, Truchetet F, Cambazard F et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-oligosaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair Regen 2012; 20: 4: 500-511. doi: 10.1111/j.1524-475X.2012.00797.x [Study conducted with Urgostart]
  2. Meaume S, Dompmartin A, Lazareth I, Sigal M, Truchetet F, Sauvadet A, Bohbot S. Quality of life in patients with leg ulcers: results from CHALLENGE, a double-blind randomized controlled trial. Journal of Wound Care 2017; 26 (7): 368-379. doi: 10.12968/jowc.2017.26.7.368 [Study conducted with Urgostart]
  3. Schmutz J.-L., Meaume S, Fays S, Ourabah Z, Guillot B, Thirion V, Collier M, Barrett S, Smith J, Bohbot S, Dompmartin A et al. Evaluation of the nano-oligosaccharide factor lopido-colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal 2008; 5(2): 172-182. [Study conducted with Urgostart contact]
  4. Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, Martini J, Petit JM, Rayman G, Lobmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3):186-196. [Study conducted with Urgostart contact]
  5. Lázaro-Martínez JL, Edmonds M, Rayman G, Apelqvist J, Van Acker K, Hartemann A, Martini J, Lobmann R, Bohbot S, Kerihuel JC, Piaggesi A. Optimal wound closure of diabetic foot ulcers with early initiation of TLC-NOSF treatment: post-hoc analysis of Explorer. J Wound Care 2019; 28(6): 358-367. doi: 10.12968/jowc.2019.28.6.358. PMID: 31166858. [Study conducted with Urgostart contact]

Interventional studies (non-comparative clinical trials)

  1. Sigal ML, Addala A, Maillard H, Chahim M, Sala F, Blaise S, Dalac S, Meaume S, Bohbot S, Tumba C, Tacca O. Clinical evaluation of a new TLC-NOSF dressing with poly-absorbent fibers for the local management of exuding leg ulcers, at the different stages of the healing process: Results from two multicentric, single-arm, prospective, open-label clinical trials. J Wound Care 2019: 28(3) :164-175. doi: 10.12968/jowc.2019.28.3.164 [Study conducted with Urgostart Plus pad]

Observational studies (real-life clinical studies)

  1. Münter KC, Meaume S, Augustin M, Senet P, Kérihuel JC. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care 2017; 26(Sup2): S4-S15. doi: 10.12968/jowc.2017.26.Sup2.S4 [Study conducted with Urgostart contact, Urgostart or Cellostart]
  2. Dissemond J, Lützkendorf S, Dietlein M, Neßeler I, Becker E, Möller U, Thomassin L, Bohbot S, Münter KC. Clinical evaluation of polyabsorbent TLC-NOSF dressings on chronic wounds: a prospective, observational, multicentre study of 1140 patients. J Wound Care 2020; 29 (6): 350-361. doi: 10.12968/jowc.2020.29.6.350 [Study conducted with Urgostart Plus pad and Urgostart Plus Border]
  3. Mai TT, & Trần QN. Tính hiệu quả và an toàn của gạc sucrose octasulfate trên vết loét bàn chân đái tháo đường: kết quả từ một nghiên cứu quan sát, nhãn mở, đa trung tâm tại Việt Nam. (Nội tiết và Đái tháo đường) Vietnam Journal of Diabetes and Endocrinology 2021; 45: 38-44. https://doi.org/10.47122/vjde.2020.45.6

Case Series & Case Reports

  1. Long Z, Jun W, Shijun Z, Dong J, Xinzhao F, Galea E. Diabetic foot ulcer management with TLC-NOSF (Technology Lipido-colloid Nano-oligosaccharide Factor) wound dressings. Wounds International 2021; 12(4): 54-61
  2. Wenge C, Xingbo Y, Jin Z et al (2022) Nano-oligosaccharide factor (sucrose octasulfate dressing based on technology lipido-colloid,TLC-NOSF) in the management of diabetic foot ulcers. The Diabetic Foot Journal 25(2): 1–6
  3. Nair HKR. Real life Experience Treating Chronic Wounds with UrgoStart Range (TLC-NOSF) – A case series. Urgo publication, 2022

CLINICAL EVIDENCE

Get in Touch with Our Representative for More Information About UrgoStart Border

Contact us

References

Guidelines, based on systematic review of clinical evidence

  1. National Institute for Health and Care Excellence (NICE). UrgoStart for treating leg ulcers and diabetic foot ulcers, https://www.nice.org.uk/guidance/mtg42, January 2019, last updated April 2023.
  2. Chen P, Campillo Vilorio N , Dhatariya K, Jeffcoate W , Lobmann R , McIntosh C , Piaggesi A , Steinberg J, Vas P, Viswanathan V, Wu S, Game F, on behalf of the International Working Group on the Diabetic Foot (IWGDF). Guidelines on interventions to enhance healing of foot ulcers in people with diabetes. IWGDF 2023 update. April 2023. Accessible at: Wound healing interventions guideline (2023 update) – IWGDF Guidelines

Systematic reviews

  1. Dissemond J, Augustin M, Dietlein M, Faust U, Keuthage W, Lobmann R, Münter KC, Strohal R, Stücker M, Traber J, Vanscheidt W, Läuchli S. Efficacy of MMP-inhibiting wound dressings in the treatment of chronic wounds: a systematic review. J Wound Care 2020 ; 29(2): 102-118.
  2. Nair H, Galea E, Deng W, Uthaipaisanwong A, Venkateshwaran N, Selva Seetha Raman S. Benefits of sucrose octasulfate (TLC-NOSF) dressings in the treatment of chronic wounds: A systematic review. Journal of Wound Care 2021; 30 (Suppl.4): S42-S52. doi: 10.12968/jowc.2021.30.Sup4.S42
  3. Vas P, Rayman G, Dhatariya K, Driver V, Hartemann A, Londahl M, Piaggesi A, Apelqvist J, Attinger C, Game F.Vas P, et al. Effectiveness of interventions to enhance healing of chronic foot ulcers in diabetes: a systematic review. Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3284. doi: 10.1002/dmrr.3284

Randomised Controlled Trials

  1. Meaume S, Truchetet F, Cambazard F et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-oligosaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair Regen 2012; 20: 4: 500-511. doi: 10.1111/j.1524-475X.2012.00797.x [Study conducted with Urgostart]
  2. Meaume S, Dompmartin A, Lazareth I, Sigal M, Truchetet F, Sauvadet A, Bohbot S. Quality of life in patients with leg ulcers: results from CHALLENGE, a double-blind randomized controlled trial. Journal of Wound Care 2017; 26 (7): 368-379. doi: 10.12968/jowc.2017.26.7.368 [Study conducted with Urgostart]
  3. Schmutz J.-L., Meaume S, Fays S, Ourabah Z, Guillot B, Thirion V, Collier M, Barrett S, Smith J, Bohbot S, Dompmartin A et al. Evaluation of the nano-oligosaccharide factor lopido-colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. International Wound Journal 2008; 5(2): 172-182. [Study conducted with Urgostart contact]
  4. Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, Martini J, Petit JM, Rayman G, Lobmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3):186-196. [Study conducted with Urgostart contact]
  5. Lázaro-Martínez JL, Edmonds M, Rayman G, Apelqvist J, Van Acker K, Hartemann A, Martini J, Lobmann R, Bohbot S, Kerihuel JC, Piaggesi A. Optimal wound closure of diabetic foot ulcers with early initiation of TLC-NOSF treatment: post-hoc analysis of Explorer. J Wound Care 2019; 28(6): 358-367. doi: 10.12968/jowc.2019.28.6.358. PMID: 31166858. [Study conducted with Urgostart contact]

Interventional studies (non-comparative clinical trials)

  1. Sigal ML, Addala A, Maillard H, Chahim M, Sala F, Blaise S, Dalac S, Meaume S, Bohbot S, Tumba C, Tacca O. Clinical evaluation of a new TLC-NOSF dressing with poly-absorbent fibers for the local management of exuding leg ulcers, at the different stages of the healing process: Results from two multicentric, single-arm, prospective, open-label clinical trials. J Wound Care 2019: 28(3) :164-175. doi: 10.12968/jowc.2019.28.3.164 [Study conducted with Urgostart Plus pad]

Observational studies (real-life clinical studies)

  1. Münter KC, Meaume S, Augustin M, Senet P, Kérihuel JC. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care 2017; 26(Sup2): S4-S15. doi: 10.12968/jowc.2017.26.Sup2.S4 [Study conducted with Urgostart contact, Urgostart or Cellostart]
  2. Dissemond J, Lützkendorf S, Dietlein M, Neßeler I, Becker E, Möller U, Thomassin L, Bohbot S, Münter KC. Clinical evaluation of polyabsorbent TLC-NOSF dressings on chronic wounds: a prospective, observational, multicentre study of 1140 patients. J Wound Care 2020; 29 (6): 350-361. doi: 10.12968/jowc.2020.29.6.350 [Study conducted with Urgostart Plus pad and Urgostart Plus Border]
  3. Mai TT, & Trần QN. Tính hiệu quả và an toàn của gạc sucrose octasulfate trên vết loét bàn chân đái tháo đường: kết quả từ một nghiên cứu quan sát, nhãn mở, đa trung tâm tại Việt Nam. (Nội tiết và Đái tháo đường) Vietnam Journal of Diabetes and Endocrinology 2021; 45: 38-44. https://doi.org/10.47122/vjde.2020.45.6

Case Series & Case Reports

  1. Long Z, Jun W, Shijun Z, Dong J, Xinzhao F, Galea E. Diabetic foot ulcer management with TLC-NOSF (Technology Lipido-colloid Nano-oligosaccharide Factor) wound dressings. Wounds International 2021; 12(4): 54-61
  2. Wenge C, Xingbo Y, Jin Z et al (2022) Nano-oligosaccharide factor (sucrose octasulfate dressing based on technology lipido-colloid,TLC-NOSF) in the management of diabetic foot ulcers. The Diabetic Foot Journal 25(2): 1–6
  3. Nair HKR. Real life Experience Treating Chronic Wounds with UrgoStart Range (TLC-NOSF) – A case series. Urgo publication, 2022

OTHER PRODUCTS

UrgoStart
UrgoStart
 View
UrgoStart Contact
UrgoStart Contact
 View

You are being redirected our of URGO Medical APAC website. The content on the subsequent website is intended for and only applicable to the market’s home audience.

Do you wish to proceed? 

No